Skip to Content

Join the 'Sofosbuvir' group to help and get support from people like you.

Sofosbuvir News

Doctors Seeing More HIV Patients With Multidrug Resistance

Posted 6 days ago by Drugs.com

THURSDAY, Dec. 1, 2016 – A significant number of people with HIV have strains of the AIDS-causing virus that are resistant to both older and newer drugs, researchers report. The researchers looked at 712 HIV patients worldwide whose infection was not controlled by antiretroviral drugs. They found that 16 percent of patients whose infection was resistant to modern drugs had HIV mutations linked with resistance to older drugs called thymidine analogues. Among patients whose HIV had this mutation, 80 percent were also resistant to tenofovir, the main drug in most modern HIV treatment and prevention programs, the researchers reported. The findings were published in the Nov. 30 issue of The Lancet Infectious Diseases journal. "We were very surprised to see that so many people were resistant to both drugs, as we didn't think this was possible," study lead author Ravi Gupta, of University ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Sovaldi, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Complera, Triumeq, Baraclude, Victrelis, Genvoya, Sofosbuvir, Zepatier, Epclusa, Viread, Viekira Pak, Kaletra, Entecavir

HIV May Hide in Tissues, Even After Treatment

Posted 27 Oct 2016 by Drugs.com

WEDNESDAY, Oct. 26, 2016 – HIV patients who've been treated with antiretroviral drugs still have the AIDS-causing virus in their tissues, a new study suggests. Treatment with antiretrovirals eliminates detectable levels of HIV in the blood and controls the disease. But the new findings suggest that HIV in the tissues may not cause AIDS but could contribute to the development of unrelated conditions, such as cancer and heart disease, according to the University of California, San Francisco (UCSF) researchers. "Looking in tissues of treated HIV patients, we found that HIV in some tissues did not appear to be affected by antiretrovirals," said study senior author Dr. Michael McGrath. "Notably we saw no evidence of drug resistance, which we would have seen if the virus had been exposed to medications," said McGrath. He is UCSF professor of laboratory medicine at the AIDS and Cancer ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Sovaldi, Ribavirin, Valacyclovir, Pre-Exposure Prophylaxis, Incivek, Zovirax, Baraclude, Victrelis, Famciclovir, Famvir, Sofosbuvir, Viread, Kaletra, Tenofovir, Diagnosis and Investigation, Entecavir, Ribasphere

FDA Medwatch Alert: Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating

Posted 10 Oct 2016 by Drugs.com

ISSUE: The FDA is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain direct-acting antiviral (DAA) medicines for hepatitis C virus. In a few cases, HBV reactivation in patients treated with DAA medicines resulted in serious liver problems or death. HBV reactivation usually occurred within 4-8 weeks. As a result, FDA is requiring a Boxed Warning, our most prominent warning, about the risk of HBV reactivation to be added to the drug labels of these DAAs directing health care professionals to screen and monitor for HBV in all patients receiving DAA treatment. This warning will also be included in the patient information leaflet or Medication Guides for these medicines. BACKGROUND: Direct-acting antiviral medicines are used to treat chronic hepatitis C virus (HCV) ... Read more

Related support groups: Hepatitis C, Harvoni, Hepatitis B, Sovaldi, Sofosbuvir, Zepatier, Epclusa, Viekira Pak, Daklinza, Ledipasvir/sofosbuvir, Olysio, Simeprevir, Viekira XR, Daclatasvir, Technivie, Ombitasvir/paritaprevir/ritonavir, Sofosbuvir/velpatasvir, Elbasvir/grazoprevir, Dasabuvir/ombitasvir/paritaprevir/ritonavir

Epclusa Approved for Chronic Hepatitis C

Posted 29 Jun 2016 by Drugs.com

TUESDAY, June 28, 2016 – The combination drug Epclusa has been approved by the U.S. Food and Drug Administration to treat the six major strains of chronic hepatitis C virus (HCV). Epclusa combines sofosbuvir, FDA-approved in 2013, and the new drug velpatasvir. For people with moderate-to-severe cirrhosis (chronic liver disease), Epclusa is approved to be used in combination with the drug ribavirin. Epclusa also is approved for use in people who haven't developed cirrhosis, the agency said Tuesday in a news release. HCV causes liver inflammation and diminished liver function. Some 75 percent of Americans with the disease have genotype 1, although there are five other strains. The disease typically becomes chronic, leading to possible complications including bleeding, yellowing of the skin and eyes (jaundice), abdominal fluid accumulation and liver cancer. It could lead to death. Epclusa ... Read more

Related support groups: Hepatitis C, Sofosbuvir, Epclusa, Sofosbuvir/velpatasvir

FDA Approves Epclusa (sofosbuvir and velpatasvir) for Treatment of all Major Forms of Chronic Hepatitis C Virus Infection

Posted 28 Jun 2016 by Drugs.com

June 28, 2016 – The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). For patients with moderate to severe cirrhosis (decompensated cirrhosis), Epclusa is approved for use in combination with the drug ribavirin. Epclusa is a fixed-dose combination tablet containing sofosbuvir, a drug approved in 2013, and velpatasvir, a new drug, and is the first to treat all six major forms of HCV. “This approval offers a management and treatment option for a wider scope of patients with chronic hepatitis C,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. There are at least six ... Read more

Related support groups: Hepatitis C, Sovaldi, Sofosbuvir, Epclusa, Sofosbuvir/velpatasvir

Generic Hepatitis C Drugs as Effective as Pricey Brand Names: Study

Posted 18 Apr 2016 by Drugs.com

SATURDAY, April 16, 2016 – Low-cost generic antiviral drugs are as effective and safe as more expensive brand-name drugs in treating people with hepatitis C, researchers report. In many countries, people don't have access to a course of brand-name direct-acting antiviral drugs due to the high cost – as much as $94,000 a patient, the researchers explained. However, mass-produced generic versions are available for less than 1 percent of the retail price of the brand-name drugs, they added. "Our interim data suggests a potential solution for hepatitis C patients in areas where treatment access has been restricted as a result of the high prices demanded for branded treatment," said study author Dr. James Freeman, of GP2U Telehealth in Hobart, Australia. The study of patients in the United States, Canada, Africa, Australia, Europe and Southeast Asia found that generic direct-acting ... Read more

Related support groups: Hepatitis C, Harvoni, Sovaldi, Ribavirin, Sofosbuvir, Liver and Pancreatic Disease, Copegus, Ribasphere, Daklinza, Ledipasvir/sofosbuvir, Rebetol, Interferon Alfa-2B/Ribavirin, Rebetron, RibaPak, Virazole, Hepatic Tumor, Daclatasvir, Moderiba, RibaTab

HIV Can Persist in Body Despite Drug Therapy

Posted 27 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 27, 2016 – Even when blood tests of HIV patients on antiretroviral drugs show no sign of the AIDS-causing virus, it can still be replicating in lymphoid tissue, researchers report. The study offers important new insight into how HIV persists in the body despite treatment with the powerful drugs, according to the team of international researchers led by Northwestern University's Feinberg School of Medicine in Chicago. To reach their finding, they examined viral sequences in samples of lymph node and blood cells from three HIV-infected patients who had no detectable virus in their blood. And what they found was that a viral reservoir in lymphoid tissue, which scientists believed held long-lived infected cells in a resting state, was being constantly replenished with infected cells. "The challenge is to deliver drugs at clinically effective concentrations to where the ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Sovaldi, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Complera, Triumeq, Baraclude, Victrelis, Genvoya, Sofosbuvir, Viread, Kaletra, Viekira Pak, Tenofovir, Diagnosis and Investigation, Norvir

In Rare Cases, Hepatitis C Drug Tied to Slowed Heart Rate: Study

Posted 4 Nov 2015 by Drugs.com

WEDNESDAY, Nov. 4, 2015 – One of the new, highly effective drugs for treating hepatitis C can cause a very slow and erratic heart rate in some patients, new research warns. Doctors at a Paris hospital found that three out of 415 chronic hepatitis C patients treated with the drug sofosbuvir during 2014 developed an abnormally slow heart rate, called an bradyarrhythmia. In all three cases, the patients were also receiving other hepatitis C medications, including daclatasvir, simeprevir and ribavirin, according to the report. "The potential cardiac toxicity of sofosbuvir-containing regimens suggests the need for caution with the use of such regimens," the Parisian doctors concluded in the report. They suggested that doctors review other medications and potential risk factors for an abnormal heart rate before prescribing the drug. And, they pointed out the possible need to monitor the ... Read more

Related support groups: Hepatitis C, Harvoni, Sovaldi, Bradyarrhythmia, Sofosbuvir, Ledipasvir/sofosbuvir

HIV Therapy May Also Lower Risk for Hepatitis B, Study Says

Posted 12 Oct 2015 by Drugs.com

MONDAY, Oct. 12, 2015 – Not only does effective HIV therapy thwart the AIDS-causing virus, it may also reduce the risk for hepatitis B infection, a new study says. "What this means to us is that effective HIV therapy appears to restore an impairment in the immune response that protects someone with HIV from acquiring hepatitis B infection," study senior author Dr. Chloe Thio, a professor of medicine at Johns Hopkins University School of Medicine, said in a university news release. The study, published in the October issue of Annals of Internal Medicine, involved 2,400 gay and bisexual men who were enrolled in the Multicenter AIDS Cohort Study. Researchers found that the men successfully treated with HIV therapy had the same risk for hepatitis B infection as the men who did not have HIV. Hepatitis B is a virus that can damage the liver. The study showed HIV-positive men on HIV therapy ... Read more

Related support groups: Harvoni, HIV Infection, Valtrex, Acyclovir, Hepatitis B, Atripla, Sovaldi, Ribavirin, Valacyclovir, Pre-Exposure Prophylaxis, Incivek, Truvada, Zovirax, Pegasys, Stribild, Triumeq, Complera, Baraclude, Famciclovir, Victrelis

Almost Half of American Adults With HIV Don't Take Meds: Report

Posted 24 Sep 2015 by Drugs.com

THURSDAY, Sept. 24, 2015 – Almost half of American adults infected with HIV don't take medications that can prevent them from developing AIDS, a new government report shows. The statistics, based on data gathered from 2007 to 2012, are a few years out of date, so it's not clear whether the situation has changed. Still, the report – an analysis of people aged 18 to 59 – suggests a widespread lack of recommended care. "Based on what we know nowadays, everyone who's HIV-positive should be on therapy," said Dr. Carlos del Rio, co-director of the Center for AIDS Research at Emory University, in Atlanta. "This highlights the challenges we have ahead because we have such an unequal epidemic." The report, authored by Dr. Joseph Woodring of the U.S. National Center for Health Statistics, estimated the prevalence of HIV infection based on a survey of more than 10,000 people. The survey found ... Read more

Related support groups: HIV Infection, Tamiflu, Sovaldi, Pre-Exposure Prophylaxis, Incivek, Baraclude, Victrelis, Sofosbuvir, Oseltamivir, Viread, Kaletra, Tenofovir, Entecavir, Norvir, Telaprevir, Lamivudine, Reyataz, Nevirapine, Boceprevir, Prezista

FDA Approves Daklinza (daclatasvir) for Chronic Hepatitis C Genotype 3 Infections

Posted 27 Jul 2015 by Drugs.com

July 24, 2015 – The U.S. Food and Drug Administration today approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections. Daklinza is the first drug that has demonstrated safety and efficacy to treat genotype 3 HCV infections without the need for co-administration of interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection. Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with HCV have no symptoms of the disease until liver damage becomes apparent, which may take several years. Some people with chronic HCV infection develop scarring and poor liver function (cirrhosis) over many years, which can lead to complications such as bleeding, jaundice (yellowish eyes or skin), fluid accumulation in the abdomen, ... Read more

Related support groups: Hepatitis C, Sofosbuvir, Daklinza, Daclatasvir

Many U.S. AIDS Patients Still Die When 'Opportunistic' Infections Strike

Posted 1 Jul 2015 by Drugs.com

WEDNESDAY, July 1, 2015 – Even after the advent of powerful medications for suppressing HIV, a new study finds that more than one-third of people in San Francisco who were diagnosed with an AIDS-related infection died within five years. "The main cause of mortality arises from people stopping treatment entirely," said Dr. Robert Grant, a professor at the University of California, San Francisco, who reviewed the findings but was not involved in the research. When HIV treatment lapses, so-called "opportunistic" infections and illnesses can arise, posing a real threat to patients' health, he explained. The bottom line, according to Grant, is that there is still "a long way to go" in prolonging the lives of Americans with HIV/AIDS. The new study was led by Dr. Sandra Schwarcz, associate professor of epidemiology and biostatistics at the University of California, San Francisco. She and her ... Read more

Related support groups: Harvoni, HIV Infection, Tamiflu, Atripla, Sovaldi, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Complera, Triumeq, Baraclude, Victrelis, Mycobacterium avium-intracellulare, Mycobacterium avium-intracellulare - Treatment, Sofosbuvir, Oseltamivir, Viread, Kaletra, Norvir

Sequence of Shots May Lead to Effective HIV Vaccine, Mouse Study Finds

Posted 25 Jun 2015 by Drugs.com

THURSDAY, June 25, 2015 – It's unlikely that a single vaccine would ever enable the body to neutralize the HIV virus, but a sequence of immunizations might hold the key, a new mouse study suggests. The immune system could be guided in a series of steps to develop a special type of HIV-fighting antibody, a team of researchers said. Each immunization would be customized for specific stages of the immune system's response to the virus. In the end, the series of shots would result in the production of broadly neutralizing antibodies capable of fighting HIV, the authors said. "As HIV mutates in a patient, the immune system continually adapts. In some patients, this process produces broadly neutralizing antibodies, which are unusual antibodies that can bind to and neutralize a wide range of globally occurring HIV variants. These are the antibodies we want to try to elicit with a vaccine," ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Sovaldi, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Complera, Triumeq, Baraclude, Victrelis, Sofosbuvir, Viread, Kaletra, Entecavir, Norvir, Tenofovir, Telaprevir, Ledipasvir/sofosbuvir

Experimental Drug Combo Shows Promise Against Hepatitis C

Posted 5 May 2015 by Drugs.com

TUESDAY, May 5, 2015 – Researchers have released yet another study finding impressive results for an experimental drug combo that aims to rid the body of infection with liver-damaging hepatitis C. In this case, a combination of three drugs in the pipeline – daclatasvir, asunaprevir and beclabuvir – effectively cleared the virus in 93 percent of patients, according to new research from Duke University in Durham, N.C. All of the patients had already developed an infection-linked scarring of the liver known as cirrhosis. None of these drugs has been approved by the U.S. Food and Drug Administration, but daclatasvir is currently under FDA review, according to a Duke news release. One U.S. expert said the drug combination could be an additional advance against hepatitis C. "This regimen is yet another all-oral treatment for the most common type of hepatitis C, which offers high cure rates ... Read more

Related support groups: Hepatitis C, Harvoni, Sovaldi, Sofosbuvir

FDA Warns of Cardiac Effect When Heart Drug Mixed With Hepatitis C Meds

Posted 25 Mar 2015 by Drugs.com

WEDNESDAY, March 25, 2015 – A potentially life-threatening slowing of the heart can occur when the common heart drug amiodarone is taken with new hepatitis C medications, the U.S. Food and Drug Administration warns. The dangerous slowing of the heart – called symptomatic bradycardia – can occur when amiodarone is taken with the hepatitis C drugs Harvoni (ledipasvir/sofosbuvir) or Sovaldi (sofosbuvir) and combined with another direct-acting antiviral for the treatment of hepatitis C. Harvoni and Sovaldi are two new medicines recently approved by the FDA to help rid the body of hepatitis C infection. If left untreated, hepatitis C infection can damage the liver and raise the odds of liver failure and liver cancer. Amiodarone is commonly used to treat heartbeat irregularities, the FDA noted in a news release. Information about the risk of the drugs used in combination is being added to ... Read more

Related support groups: Hepatitis C, Harvoni, Amiodarone, Sovaldi, Bradyarrhythmia, Sofosbuvir, Cordarone, Pacerone, Nexterone, Cordarone IV

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Hepatitis C

Related Drug Support Groups

Sovaldi

Sofosbuvir Patient Information at Drugs.com